NEW DELHI: The human clinical trials of two COVID-19 vaccine candidates developed indigenously by Bharat Biotech in collaboration with ICMR and Zydus Cadila Ltd have moved to Phase 2, ICMR Director-General Dr Balram Bhargava said.
“Recombinant Oxford vaccine being manufactured by Serum Institute was given approval for Phase 2 and 3 trials which would start within a week,” Bhargava added.
COVAXIN, India’s first indigenous coronavirus vaccine developed by Bharat Biotech in collaboration with ICMR, and Zydus Cadila’s ZyCoV-D, a DNA vaccine against the SARS-CoV-2, have shown satisfactory results in preclinical studies.
Giving an update related to the COVID-19 vaccine, the ICMR top boss said that there is no specific drug and vaccine available yet for the disease caused by coronavirus.
States should analyse #testing data & mount locally specific data-driven response at their levels#COVID19 Vaccine: Prioritization & fair distribution, logistics of roll-out in cold chain, stock-piling & training of people crucial – DG, @ICMRDELHIhttps://t.co/EKiHB5OkNZ 3/3🧵 pic.twitter.com/AYkUSfJwhj— PIB in Maharashtra 🇮🇳 (@PIBMumbai) August 4, 2020